{"denoms":[{"counts":[{"groupId":"BG000","value":"664"},{"groupId":"BG001","value":"670"},{"groupId":"BG002","value":"1334"}],"units":"Participants"}],"groups":[{"description":"Brentuximab vedotin 1.2 milligram per kilogram (mg/kg), infusion, intravenously over 30-minutes plus doxorubicin 25 milligram per square meter (mg/m\\^2), vinblastine 6 mg/m\\^2, and dacarbazine 375 mg/m\\^2, infusion, intravenously, once on Days 1 and 15 of each 28-day treatment cycle for up to a maximum of 6 cycles. Brentuximab vedotin was administered within approximately 1 hour after completion of AVD.","id":"BG000","title":"A+AVD"},{"description":"Doxorubicin 25 mg/m\\^2, bleomycin 10 units per square meter (units/m\\^2), vinblastine 6 mg/m\\^2, and dacarbazine 375 mg/m\\^2, infusion, intravenously, once on Days 1 and 15 of each 28-day treatment cycle for up to a maximum of 6 cycles.","id":"BG001","title":"ABVD"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"15.83","value":"38.8"},{"groupId":"BG001","spread":"16.05","value":"40.2"},{"groupId":"BG002","spread":"15.95","value":"39.5"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","populationDescription":"The ITT population included all participants randomized to treatment.","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"286"},{"groupId":"BG001","value":"272"},{"groupId":"BG002","value":"558"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"378"},{"groupId":"BG001","value":"398"},{"groupId":"BG002","value":"776"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The ITT population included all participants randomized to treatment.","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"51"},{"groupId":"BG001","value":"55"},{"groupId":"BG002","value":"106"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"571"},{"groupId":"BG001","value":"577"},{"groupId":"BG002","value":"1148"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"42"},{"groupId":"BG001","value":"38"},{"groupId":"BG002","value":"80"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The ITT population included all participants randomized to treatment.","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"56"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"113"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"45"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"560"},{"groupId":"BG001","value":"554"},{"groupId":"BG002","value":"1114"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"35"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"27"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The ITT population included all participants randomized to treatment.","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"}],"populationDescription":"The intent-to-treat (ITT) population included all participants randomized to treatment."}